To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the response of patients with Intermediate or High
Risk myelodysplastic syndromes (MDS) following treatment with decitabine or azacitidine.